Drug intelligence / Profile preview

moxifloxacin + nepafenac + prednisolone acetate

Development stage
Phase 4
Lead developer
Harrow
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

This is an **ophthalmic combination drug** containing three active ingredients: - **Moxifloxacin**: a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to interruption of bacterial DNA replication, transcription, and repair. It is used for bacterial infections of the eye[2][4][6]. - **Nepafenac**: a nonsteroidal anti-inflammatory drug (NSAID) that acts as a prodrug, converted in ocular tissues to amfenac, which inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and hence decreasing inflammation and pain related to ocular surgery or injury. - **Prednisolone acetate**: a synthetic glucocorticoid corticosteroid that suppresses inflammation by inhibiting multiple inflammatory cytokines and decreasing leukocyte infiltration. Used for ocular inflammatory conditions. Together, this combination is used primarily for **the prevention and treatment of infection and inflammation associated with ocular surgery or injury**[1][3][7]. The mechanism combines antibacterial, anti-inflammatory (steroidal), and anti-inflammatory (nonsteroidal) actions.

Other names
moxifloxacin/nepafenac/prednisolone ophthalmicprednisolone ac-moxiflox-nepaf
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DNA gyraseGR (Glucocorticoid receptor)Topo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on moxifloxacin + nepafenac + prednisolone acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on moxifloxacin + nepafenac + prednisolone acetate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call